Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
Bristol-Myers Squibb (BMS)
Patients eligible to participate in this trial will be randomly assigned to receive one of three treatment regimes. The treatment regimes are: chemotherapy alone, chemotherapy with Nivolumab and a BMS-986205 placebo, or chemotherapy with Nivolumab and BMS-986205. All treatment regimes will also include radical cystectomy surgery.